TY  - JOUR
A1  - Pennekamp, Frank
A1  - Iles, Alison C.
A1  - Garland, Joshua
A1  - Brennan, Georgina
A1  - Brose, Ulrich
A1  - Gaedke, Ursula
A1  - Jacob, Ute
A1  - Kratina, Pavel
A1  - Matthews, Blake
A1  - Munch, Stephan
A1  - Novak, Mark
A1  - Palamara, Gian Marco
A1  - Rall, Bjorn C.
A1  - Rosenbaum, Benjamin
A1  - Tabi, Andrea
A1  - Ward, Colette
A1  - Williams, Richard
A1  - Ye, Hao
A1  - Petchey, Owen L.
T1  - The intrinsic predictability of ecological time series and its potential to guide forecasting
JF  - Ecological monographs : a publication of the Ecological Society of America.
KW  - empirical dynamic modelling
KW  - forecasting
KW  - information theory
KW  - permutation entropy
KW  - population dynamics
KW  - time series analysis
Y1  - 2019
U6  - https://doi.org/10.1002/ecm.1359
SN  - 0012-9615
SN  - 1557-7015
VL  - 89
IS  - 2
PB  - Wiley
CY  - Hoboken
ER  - 
TY  - JOUR
A1  - Peter, Lena
A1  - Wendering, Désirée Jacqueline
A1  - Schlickeiser, Stephan
A1  - Hoffmann, Henrike
A1  - Noster, Rebecca
A1  - Wagner, Dimitrios Laurin
A1  - Zarrinrad, Ghazaleh
A1  - Münch, Sandra
A1  - Picht, Samira
A1  - Schulenberg, Sarah
A1  - Moradian, Hanieh
A1  - Mashreghi, Mir-Farzin
A1  - Klein, Oliver
A1  - Gossen, Manfred
A1  - Roch, Toralf
A1  - Babel, Nina
A1  - Reinke, Petra
A1  - Volk, Hans-Dieter
A1  - Amini, Leila
A1  - Schmueck-Henneresse, Michael
T1  - Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
JF  - Molecular therapy methods and clinical development
N2  - Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.
Y1  - 2022
U6  - https://doi.org/10.1016/j.omtm.2022.02.012
SN  - 2329-0501
VL  - 25
SP  - 52
EP  - 73
PB  - Cell Press
CY  - Cambridge
ER  -